TREAT (Telemedicine for Reach, Education, Access, and Treatment)

Type 2 Diabetes Clinical Trial

— TREAT  

Official title:

TREAT (Telemedicine for Reach, Education, Access, and Treatment)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01339208
• Other study ID #: PRO10100547
• Status: Completed
• Phase: N/A
• First received: April 14, 2011
• Last updated: May 26, 2015
• Start date: June 2011
• Est. completion date: March 2015

Study information

• Verified date: April 2011
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility and clinical efficacy of an innovative care model that combines Telemedicine consultations, educator therapeutic management and diabetes education to empower patients to be in greater control of their own diabetes care for improvements in diabetes outcomes.

Description:

This study will assess whether a new care delivery model combining telemedicine videoconference diabetes consultations with diabetes self-management teaching is efficacious in reducing HbA1c in patients with type 2 diabetes in rural areas. The control group will consist of patients with type 2 diabetes receiving "usual care", i.e., who have not received a referral to the endocrinologist telemedicine team. Secondary outcomes include patient satisfaction, level of understanding of self-management skills, and hypoglycemia

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older with type 2 diabetes

• Referral by a primary care provider.

• HbA1c equal or greater than 7.0%.

Exclusion Criteria:

• Type 1 diabetes

• Gestational Diabetes

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Other:
• Telemedicine diabetes intervention
3 month duration telemedicine consultation and diabetes education

Locations

Country	Name	City	State
United States	UPMC Northwest	Seneca	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
University of Pittsburgh	United States Department of Defense

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in HbA1c % from baseline		3 and 6 month	No
Secondary	Patient satisfaction		6 month	No